The data underlying the results presented in the study are either within the manuscript or available through ClinVar at the NCBI <https://www.ncbi.nlm.nih.gov/clinvar/?term=APC%5Bgene%5D>.

Introduction {#sec001}
============

Multi-gene panel testing is now routine for identifying hereditary cancer susceptibility, leading to increased detection of pathogenic mutations, which can improve clinical management. However, testing often identifies variants of uncertain significance (VUS), which are often missense amino acid (AA) substitutions, small in frame deletions and duplications, or non-coding changes \[[@pone.0233673.ref001], [@pone.0233673.ref002]\]. VUS in genes that predispose to hereditary cancer and other disorders are rapidly accumulating in variant databases. For example, the ClinVar database at the National Center for Biotechnology Information at the United States National Library of Medicine provides a freely accessible archive of variants with assertions regarding the pathogenicity of each variant with the indicated phenotype from submitting laboratories and expert panels \[[@pone.0233673.ref003]\]. The classification of these VUS represents a major challenge in clinical genetics.

Computational *(in silico)* tools have been developed to help predict whether or not the protein function will be disrupted (reviewed in \[[@pone.0233673.ref004]\]). *In silico* tools often use Protein Multiple Sequence Alignments (PMSA) to consider the evolutionary conservation and biophysical properties of the wild type and variant protein to make predictions of pathogenicity. PMSA-based computational methods are complicated to use properly (reviewed in \[[@pone.0233673.ref004]\]). The PMSA must be of high quality and sample enough species to provide reliable data \[[@pone.0233673.ref005], [@pone.0233673.ref006]\]. These *in silico* methods have been validated for relatively few hereditary cancer genes in which pathogenic missense variants are not rare (BRCA1/2, the mismatch repair \[MMR\] genes, TP53, a few others) \[[@pone.0233673.ref005], [@pone.0233673.ref007]--[@pone.0233673.ref011]\]. They have not often been validated for other genes, and for some genes predictive value was not strong \[[@pone.0233673.ref012]\]. However, they are often cited as evidence in favor or against pathogenicity of variants for genes in which validation is lacking. The American College of Genetics and Genomics (ACMG) and the Association for Molecular Pathology (AMP) published guidelines for evaluating the pathogenicity of variants in Mendelian disease genes, including general rules for the use of *in silico* tools \[[@pone.0233673.ref013]\].

Missense pathogenic variants are rare in some genes, including *APC*, the gene responsible for Familial Adenomatous Polyposis (FAP). *APC* has been sequenced frequently in clinical genetic testing, but few missense pathogenic variants have been identified, for reasons that have not been clearly demonstrated \[[@pone.0233673.ref014]\]. The increase in clinical DNA sequencing tests for cancer predisposition has led to an increase in missense VUSs in APC that require classification.

Here we systematically apply *in silico* methods to *APC*, assessing the logistics and results of using these commonly available tools to predict pathogenicity of missense variants in a gene for which missense is an uncommon mechanism of pathogenicity.

Materials and methods {#sec002}
=====================

Sequence and variant data are publically available from databases at the NLM. The study protocol was determined to be exempt from human subject regulations by Western IRB, as the data were de-identified.

APC sequences and multiple sequence alignments, phylogenetic analysis {#sec003}
---------------------------------------------------------------------

Amino acid sequences were collected by searching NCBI's online Gene database (<http://www.ncbi.nlm.nih.gov/gene>), for "APC" in 2013, 2015, and 2018. PMSAs were made using Clustal Omega from the European Bioinformatics Institute (EBI) (<https://www.ebi.ac.uk/Tools/msa/clustalo>) and MUSCLE v3.8.31 \[[@pone.0233673.ref015]\] and examined using Mesquite, a software for evolutionary biology (<http://mesquiteproject.wikispaces.com/>) \[[@pone.0233673.ref016]\].

Misaligned areas were manually adjusted after the MUSCLE alignment. Gaps and insertions in the PMSA were analyzed to determine if the sequences in question were likely true indels or likely to be artifacts of computer analysis of genome annotation. BLAST searches were performed of inserted runs of AAs that did not align with any other species in our PMSA, using Protein BLAST, with default settings and query sequences of minimum length 30. For a "positive BLAST", the sequence results needed to show the presence of either homologs of the query sequence in APC from other organisms or from known protein domains. For a "negative BLAST", the only result was the sequence from the species used in the search query. Exon boundaries were identified using the NCBI Gene Database. If an entire exon from one species did not align with the other sequences and was deemed BLAST negative, that exon was removed from the PMSA, using the rationale that it would be irrelevant to a variant found in humans.

Phylogenetic trees were constructed from the curated APC alignment using a Maximum Parsimony-based method implemented in PAUP\* (Phylogenetic Analysis Using Parsimony \[\*and Other Methods\]), Version 4, Maximum Likelihood \[[@pone.0233673.ref017], [@pone.0233673.ref018]\], and Bayesian method as implemented in MrBayes \[[@pone.0233673.ref019]\].

Nucleotide regions flanking prospective indels were analyzed using two splice site calculators: (1) SpliceSiteFrame, (<http://ibis.tau.ac.il/ssat/SpliceSiteFrame.htm>), a splice site calculator from Tel Aviv University, and (2) the online tool from the GENIE program \[[@pone.0233673.ref020]\] (<http://rulai.cshl.edu/new_alt_exon_db2/HTML/score.html>), The maximum 3' score for a perfect splice site would be 14.2, and the score for a perfect 5' splice score would be 12.6; these rarely occur. Average scores for the 3' and 5' sites are 7.9 and 8.1 respectively.

### Substitution per site {#sec004}

Absolute conservation of an amino acid in a PMSA can be determined with statistical significance (P\<0.05) if the PMSA contains at least three substitutions per site (subs/site, i.e., three times as many variants among all sequences as there are codons in the gene \[[@pone.0233673.ref005], [@pone.0233673.ref006]\]. In order to determine if APC alignments contained three subs/site, we used the PHYLIP (Phylogeny Inference Package) version 3.6a2 ProtPars program form the University of Washington, Department of Genetics (<http://evolution.genetics.washington.edu/phylip.html>), with the alignment converted to PHYLIP format. To convert the alignment from Clustal Omega format to PHYLIP format and all other formats used during the analyses, the EMBOSS Seqret from EBI (<https://www.ebi.ac.uk/Tools/sfc/emboss_seqret/>) and Mesquite Version 3.51 tools were used (<https://www.mesquiteproject.org/>).

Predictions of effects of APC missense substitutions {#sec005}
----------------------------------------------------

In July 2013, 46 APC missense variants were collected from the LOVD database maintained by the International Society for Gastrointestinal Hereditary Tumors (InSiGHT). On May 30, 2018, 4891 variants observed by clinical genetic testing were collected from the ClinVar database (<http://www.ncbi.nlm.nih.gov/clinvar/>).

### Computational algorithms {#sec006}

The pathogenicity of each missense variant recorded in ClinVar was predicted using the programs Align-GVGD, SIFT, PolyPhen2 MAPP, and REVEL. *AlignGVGD* uses PMSAs and the biophysical properties of amino acid substitutions to calculate the range of variation at each position. Each variant is assigned a grade of C65 to C0 representing decreasing probability of deleterious, with C0 representing likely neutral AA substitutions \[[@pone.0233673.ref021]\]. (<http://agvgd.hci.utah.edu/about.php>).

***SIFT*** *(Sorting Intolerant From Tolerant)* creates position specific scoring matrices derived from PMSAs. Each missense substitution predicted as "Tolerated' or "Affects Protein Function" \[[@pone.0233673.ref022]\]. (<http://sift.bii.a-star.edu.sg/>).

***PolyPhen2*** combines its own pre-built sequence alignment with protein structural characteristics, calculating a score used to classify each variant into three categories: benign, possibly damaging and probably damaging. (<http://genetics.bwh.harvard.edu/pph2/index.shtml>) \[[@pone.0233673.ref023]\]. We combined the categories of "possibly damaging" and "probably damaging".

***MAPP*** *(Multivariate Analysis of Protein Polymorphisms)* also combines a PMSA with the physiochemical characteristics of each AA position, predicting which AA should be deleterious and which should be neutral at each position in the PMSA \[[@pone.0233673.ref024]\] (<http://www.ngrl.org.uk/Manchester/page/mapp-multivariate-analysis-protein-polymorphism>).

***REVEL*** *(Rare Exome Variant Ensemble Learner)* \[[@pone.0233673.ref025]\] is an ensemble method that uses machine learning to combine the results of 13 individual predictors, using independent test sets that did not overlap with sets used to train its component features. REVEL output classes were designated as "Deleterious" for variants with a REVEL score ≥ 0.5 and "Neutral" with a REVEL score \< 0.5 \[[@pone.0233673.ref025]\].

Results {#sec007}
=======

PMSA creation {#sec008}
-------------

Results from searching the NCBI Gene database for "APC" initially yielded reliable full length APC protein sequences from 38 organisms. We encountered a number of challenges to the simple automated assembly of a meaningful APC PMSA, including:

a.  *Large inconsistencies with the APC human sequence*. In order to include only sequences which accurately reflect human biology, such sequences were omitted.

b.  *Multiple APC isoforms were found for 21 organisms*. To choose the most appropriate isoform, all 104 sequences were aligned using Clustal2W. Isoforms that lacked a common beginning protein sequence of MAA were deleted (N = 26). When duplicate sequences were found for the same species, the more complete sequence was used, and if similar length isoforms of the same organism were found with a common sequence initiation, the lowest number isoform was chosen.

c.  *Large deletions or insertions*. Many of these could easily be identified as errors in automated identification of exon-intron boundaries. In most cases we could identify the appropriate boundary and either insert or delete the appropriate sequence. For insertions that were unique to one organism, especially in areas of otherwise high homology, BLAST was used to seek other homologues of the inserted sequence, and assessed the relevant nucleotide sequence for plausible overlooked splice sites.

d.  *Small deletions or insertions*. Short gaps that were confirmed to occur distant from an exon-intron boundary were allowed. The longest such gap was AA 1631--1637 in *Loxodonta africana* (African elephant) and *Trichechus manatus latirostris* (Florida manatee), a highly conserved region in other sequences. Because of the close taxonomic relationship between these two organisms, and the fact that their sequence was assembled on the same Broad Institute platform as many other species in our alignment that lack the deletion, we assessed this gap as likely real.

We constructed two PMSAs. Our goal was to create a curated PMSA that would optimize predictions for pathogenicity of variants from computational algorithms. This 10-sequence PMSA contained species chosen to reflect as closely as possible the 14-species PMSA previously reported for analyzing variants and validating computational algorithms in the MMR genes, in which missense VUS are common and *in silico* interpretation is frequently used \[[@pone.0233673.ref007]\]. We identified full length APC sequences for 11 of these 14 species. The 10-species PMSA that we curated using the above criteria ([Table 1](#pone.0233673.t001){ref-type="table"}, PMSA excerpt in [Fig 1](#pone.0233673.g001){ref-type="fig"}, full PMSA in [S1 Fig](#pone.0233673.s001){ref-type="supplementary-material"}) contained five mammalian APC sequences plus chicken (*Gallus gallus*), frog (*Xenopus laevis*), zebrafish (*Danio rerio*), sea urchin (*Strongylocentrotus purpuratus*), and sea squirt (*Ciona intestinalis*). A larger PMSA with the full set of 38 full length sequences also was constructed, with reconstitution of obvious missing exons but no detailed curation ([S2 Fig](#pone.0233673.s002){ref-type="supplementary-material"}).

![Excerpt of the curated APC alignment generated from the MSA program Clustal Omega.\
Exon boundaries are labeled in red with a black background. The red highlighted region in the human sequence corresponds to a portion of an Armadillo Repeat domain.](pone.0233673.g001){#pone.0233673.g001}

10.1371/journal.pone.0233673.t001

###### APC amino acid sequences from the NCBI database used in the ten species APC Protein Multiple Sequence Alignment (PMSA) and phylogenetic tree.

![](pone.0233673.t001){#pone.0233673.t001g}

  Species                                        APC
  ---------------------------------------------- ----------------
  Human (*Homo sapiens)*                         AAA03586.1
  Monkey (*Macaca mulatta*)                      XP_014996065.1
  Cow (*Bos taurus)*                             NP_001069454.2
  Mouse (*Mus musculus*)                         NP_031488.2
  Opossum (*Monodelphis domestica*)              XP_007497871.1
  Chicken (*Gallus gallus*)                      XP_004949340.1
  Frog (*Xenopus laevis*)                        NP_001084351.1
  Zebrafish (*Danio rerio*)                      NP_001137312.1
  Sea urchin (*Strongylocentrotus purpuratus*)   XP_783363.3
  Sea squirt (*Ciona intestinalis*)              XP_018668496.1

Manual curation was often necessary to identify and label correct exon-intron boundaries and address insertions, gaps, and poorly-conserved areas where the alignment was less certain. A small amount of manual curation of gaps and insertions was required for vertebrate species. The intronic regions flanking large insertions were examined and assessed as potential splice sites. Sites with a high splice score (see [Methods](#sec002){ref-type="sec"}) were interpreted as actual splice sites and retained for creation of the phylogenetic tree. Inserted sequences flanked by a lower than average splice site were omitted from further analyses.

More extensive manual curation was required for *C*. *intestinalis* and *S*. *purpuratus*, the most distant species used, to ensure an accurate alignment and tree. Using BLAST+ on insertions in sea squirt and sea urchin that were not present in the human sequence, we identified sequences with little homology on inspection to the vertebrate APC sequences. Exon 1 (M1 to Q46) and Exon 5, 6, and 7 (A265 to K414) of sea squirt (*C*. *intestinalis*) and exon 6 (A260 to F477) of sea urchin *(S*. *purpuratus*) did not align with the other APC sequences, returned negative BLAST results, and were removed from the final PMSA. A region of *S*.*purpuratus* was found with homology to a spindle fiber sequence, and a long region in its C-terminus was homologous to a herpesvirus sequence. Because the exons containing these sequences also contained regions with high homology to APC, the full exons were retained in our PMSA. A large insertion in *S*. *purpuratus* containing many consecutive glutamines presumably represents a coding region microsatellite. Sequences flanking this insertion were found with high splice scores, so it was kept in the alignment.

Evolutionary rate of APC {#sec009}
------------------------

To predict if a given invariant position is invariant with statistical significance (\>95% probability), the PMSA must contain \>3.0 substitutions/site \[[@pone.0233673.ref005], [@pone.0233673.ref006]\]. In addition to our ten-sequence PMSA, curated alignments were created of nine and eight sequences that omitted the more distant species *Ciona intestinalis* (sea squirt) and *Strongylocentrotus purpuratus* (sea urchin) ([S3](#pone.0233673.s003){ref-type="supplementary-material"} and [S4](#pone.0233673.s004){ref-type="supplementary-material"} Figs). Applying the PHYLIP ProtPars package to the curated 8, 9, and 10 species APC PMSAs, we calculated that our ten species curated *APC* alignment contained 3.3 substitutions per site (subs/site), sufficient for proceeding with subsequent analyses (see [Methods](#sec002){ref-type="sec"}). Both eight- and nine-sequence PMSAs, omitting the nonvertebrate species, contained fewer than three subs/site. We calculated subs/site for six other PMSAs of cancer susceptibility genes found on the Align-GVGD website using the same 10 species ([Table 2](#pone.0233673.t002){ref-type="table"}). *APC* had a comparable evolutionary rate with *CHEK2* and *PMS2*, whereas three MMR genes (*MLH1*, *MSH2*, *MSH6*) were better conserved (1.6--2.1 subs/site), and *RAD51* was the most well-conserved of the seven genes (0.62 subs/site).

10.1371/journal.pone.0233673.t002

###### Substitutions per site in PMSAs of seven hereditary cancer genes.
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  Protein   Substitutions per site
  --------- ------------------------
  PMS2      3.4
  APC       3.3
  CHEK2     3.2
  MSH6      2.8
  MLH1      2.1
  MSH2      1.6
  RAD51     0.62

Calculations using 10 species listed in [Table 1](#pone.0233673.t001){ref-type="table"}, with evolutionary depth to sea squirt, using the PHYLIP ProtPars package.

Phylogenetic tree construction {#sec010}
------------------------------

Phylogenetic trees were generated using Bayesian, Maximum Likelihood, and Maximum Parsimony -based methods. The methods yielded similar trees, and the Maximum Parsimony -based examples are displayed in [Fig 2A](#pone.0233673.g002){ref-type="fig"} (10 species) and 2B (38 species). The relationships of the *APC* sequences among different species was as expected with sea urchin and sea squirt as the most distantly related organisms to humans.

![A. Ten species phylogenetic consensus tree for the APC protein constructed using the computational phylogenetics program PAUP\* (Phylogenetic Analysis Using Parsimony \*and other methods). B. Thirty-eight species phylogenetic consensus tree for the APC protein constructed using the computational phylogenetics program PAUP\* (Phylogenetic Analysis Using Parsimony \*and other methods).](pone.0233673.g002){#pone.0233673.g002}

*APC* variants from public databases {#sec011}
------------------------------------

In the LOVD database maintained by the International Society for Gastrointestinal Hereditary Tumors (InSiGHT), in July 2013 there were a total of 46 *APC* missense variants. In ClinVar in July 2018, there were a total of 4891 *APC* variants, of which 1988 are missense. Using filters of "missense, pathogenic, likely pathogenic", yielded nine variants in the ClinVar database with assertions of Pathogenic/Likely Pathogenic (P/LP) and no conflicting interpretations of pathogenicity per ClinVar criteria. Upon further examination, it was determined that two variants were somatic mutations, and the pathogenicity of the other seven variants were inferred to be from a splicing abnormality. Six were found to occur at canonical splice sites, and the seventh occurs within an Exonic Splicing Enhancer sequence, with confirming RNA and *in vitro* evidence of splicing alterations \[[@pone.0233673.ref026]\] ([Table 3](#pone.0233673.t003){ref-type="table"}). Thus, no pathogenic missense germline *APC* variants were documented in ClinVar using these search parameters. There are n = 21 variants (1.3% of all missense variants) with assertions of Benign or Likely Benign (B/LB). All of these were classified using criteria other than *in silico* algorithms. Of the remaining variants in ClinVar, 93.5% of the missense variants are reported as "Unknown Significance"; the rest are classified as either "Other", or display conflicting assertions of pathogenicity ([Table 4](#pone.0233673.t004){ref-type="table"}).

10.1371/journal.pone.0233673.t003

###### Nine APC missense variants using filters for "missense, pathogenic, likely pathogenic".
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  APC Classified Pathogenic Variant   ClinVar Classification   Type of Variant
  ----------------------------------- ------------------------ -----------------------------
  R141S                               Pathogenic               Splice Site
  K516N                               Pathogenic               Splice Site
  K581N                               Likely Pathogenic        Splice Site
  S634R                               Likely Pathogenic        Exonic Splice Enhancer site
  R653M                               Pathogenic               Splice Site
  R653G                               Pathogenic               Splice Site
  R653K                               Pathogenic               Splice Site
  G1120E                              Pathogenic               Somatic
  S1395C                              Pathogenic               Somatic

Two putative Pathogenic variants are due to somatic mutations, six are located in canonical splice sites and one occurs within an Exonic Splicing Enhancer sequence.

10.1371/journal.pone.0233673.t004

###### Proportion of APC missense variants from the NCBI ClinVar database with each clinical significance classification.
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  ClinVar "Clinical Significance" for APC        Missense Variants (N = 1924)
  ---------------------------------------------- ------------------------------
  Benign/Likely Benign                           21 (1.1%)
  Pathogenic/Likely Pathogenic                   0 (0%)
  Uncertain Significance                         1800 (93.5%)
  Conflicting Interpretations of Pathogenicity   103 (5.4%)

Substitutions flanking the 12 splice sites found in Human APC were removed from the list of selected missense variants. A total of 1924 variants that met the above classification criteria and were not located in exon boundaries were used for analysis. Of the 1924 variants, 1.1% were classified as benign, none were classified as pathogenic and 98.9% were classified as uncertain or conflicting interpretation of pathogenicity.

Computational methods to classify APC variants {#sec012}
----------------------------------------------

To predict the pathogenic effects of missense substitutions, multiple computational algorithms based on PMSAs and evolutionary conservation have been developed. We applied five of these tools (SIFT, PolyPhen2, Align-GVGD, MAPP, REVEL) to analyze *APC* missense variants.

For the n = 21 variants classified in ClinVar as B/LB, the prediction algorithms showed good concordance with each other and with the ClinVar classifications ([Table 5](#pone.0233673.t005){ref-type="table"}). REVEL and A-GVGD showed 100% concordance with ClinVar, SIFT predicted 95.5%, PolyPhen2 81.8%, and MAPP 77.8% to be Neutral. For the n = 1904 variants classified as VUS, "Other", or conflicting, the output differed significantly among the four non-aggregating methods (excluding REVEL). The proportion of variants predicted to be "Benign" were MAPP 25.0%, PolyPhen2 41.0%, SIFT 68.1%, Align-GVGD 82.5% ([Table 4](#pone.0233673.t004){ref-type="table"}). For MAPP, we initially used the cutoff score of 4.5 previously established to distinguish P/LP from B/LB *MLH1* and *MSH2* variants \[[@pone.0233673.ref007]\]. This cutoff predicted 75% of APC VUS to be pathogenic, an improbable proportion. With no known pathogenic missense variants, it is unclear what cutoff score is appropriate. The lowest MAPP cutoff score (34.79) that achieved a specificity and total accuracy of 100% for classifying benign variants predicts 2.6% of VUS as pathogenic.

10.1371/journal.pone.0233673.t005

###### Predictions of substitution severity with different *in silico* programs.
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                                                                            Benign Variants (N = 21)   VUS (N = 1904)                    
  ------------------------------------ ------------------------------------ -------------------------- ---------------- ---------------- ------------------
  ClinVar                              Pathogenic                           0 (0%)                     \-               \-               \-
                                       Benign                               21 (100%)                                                    \-
  REVEL                                Deleterious (REVEL score ≥ 0.5)      0 (0%)                     100%             100%             N/A
                                       Neutral (REVEL score \< 0.5)         21 (100%)                                                    N/A
  A-GVGD                               Class C65 (Deleterious moderate)     0 (0%)                     100%             100%             **77 (4.0%)**
  Class C55 (Deleterious supporting)   0 (0%)                                                                           **37 (1.9%)**    
  Class C45 (Deleterious supporting)   0 (0%)                                                                           **8 (0.42%)**    
  Class C35 (Deleterious supporting)   0 (0%)                                                                           **27 (1.4%)**    
                                       Class C25 (Deleterious supporting)   0 (0%)                                                       **64 (3.3%)**
  Class C15 (Deleterious supporting)   0 (0%)                                                                           **120 (6.3%)**   
                                       Class C0 (Neutral)                   21 (100%)                                                    **1571 (82.5%)**
  SIFT                                 Deleterious                          1 (4.8%)                   95.4%            95.2%            **608 (31.9%)**
                                       Tolerated                            20 (95.2%)                                                   **1296 (68.1%)**
  PolyPhen2                            Probably Damaging                    1 (4.8%)                   84.0%            80.9%            **814 (42.8%)**
                                       Possibly Damaging                    3 (13.3%)                                                    **309 (16.2%)**
                                       Benign                               17 (80.9%)                                                   **781 (41.0%)**
  MAPP                                 Pathogenic (MAPP score ≥ 4.5)        5 (23.8%)                  80.7%            76.2%            **1428 (75.0%)**
                                       Neutral (MAPP score \< 4.5)          16 (76.2%)                                                   **476 (25.0%)**

Predictions of pathogenicity for APC missense variants were made using REVEL, A-GVGD, SIFT, PolyPhen2 and MAPP. REVEL output classes were designated as "Deleterious" for variants with a REVEL score ≥ 0.5 and "Neutral" with a REVEL score \< 0.5 \[[@pone.0233673.ref025]\]. Assigning A-GVGD output Classes as "Neutral", "Deleterious moderate" and "Deleterious supporting" are based on probabilities from \[[@pone.0233673.ref027]\] and quantitative modeling of the ACMG/AMP criteria for assigning pathogenicity \[[@pone.0233673.ref013], [@pone.0233673.ref028]\]. SIFT predicts substitutions with SIFT scores less than 0.05 as "Deleterious" and scores equal to or greater than 0.05 as "Tolerated" \[[@pone.0233673.ref022]\]. PolyPhen2 predicts variants based on a Position Specific Independent Count (PSIC) score as "Benign" and "Probably Damaging" with high confidence, while a prediction of "Possibly Damaging" is predicted to be damaging, but with low confidence \[[@pone.0233673.ref023]\]. For MAPP, we used a cutoff score of 4.5 to predict "Pathogenic" versus "Neutral" substitutions based the cutoff used to distinguish pathogenic and neutral variants for MLH1 and MSH2 \[[@pone.0233673.ref007]\].

We explored the hypothesis that protein structural features would be associated with the likelihood that a VUS was pathogenic or benign. APC contains multiple repeats of the β-catenin binding and armadillo repeats, plus domains for oligomerization, and binding to microtubules, and EB1 and DLG proteins \[[@pone.0233673.ref029]\]. We hypothesized that missense variants 1) in the β-catenin binding and armadillo repeats would be neutral, since there was domain redundancy, 2) in the non-repeated domains would be more likely to be pathogenic, and 3) in unstructured regions would be neutral. There was no difference in the distribution of variants classified in ClinVar as neutral versus VUS relative to the beta catenin, armadillo, or other domains ([Table 6](#pone.0233673.t006){ref-type="table"}).

10.1371/journal.pone.0233673.t006

###### Proportion of benign/likely benign variants and variants of unknown significance by APC protein structural feature.
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  Domain          Benign/Likely Benign   Unknown Significance
  --------------- ---------------------- ----------------------
  Beta catenin    5 (23.8%)              606 (31.8%)
  Armadillo       1 (4.8%)               156 (8.2%)
  Other domains   4 (19.0%)              378 (19.9%)
  Not in domain   11 (52.4%)             764 (40.1%)
  Total           21 (100%)              1904 (100%)

Per our examination of the ClinVar database in May 2018, all APC missense mutations noted as P/LP were found to be somatic mutations, or located in canonical splice sites, or located in Exonic Splicing Enhancer sequences. Shortly after we closed our data set, p.S1028N, located in the first of four highly conserved 15-amino acid repeats within the β-catenin binding domain, was submitted to ClinVar by Ambry Genetics and classified as Likely Pathogenic. The evidence for this classification includes, as per the ACMG/AMP guidelines, segregation score (PP1_Strong, six meioses), phenotype score (PS4_Moderate), functional domain (PM1 \[[@pone.0233673.ref030]\]), population frequency score (PM2_Supporting) and *in silico* data (PP3). There is no evidence of splice abnormality. This variant would reach LP regardless of *in silico* analysis. Further scrutiny of variants in this region demonstrates one other variant, p.N1026S, classified as "Conflicting Interpretations of Pathogenicity" in ClinVar, which satisfies the ACMG/AMP guidelines as LP. The same criteria (PP1_Strong, PS4_Moderate, PM1, PM2) can be applied to p.N1026S, in addition to a functional defect (PS3) as reported in the literature \[[@pone.0233673.ref030], [@pone.0233673.ref031]\]. N1026 and S1028 are both located in the first 15-amino acid repeat of the β-catenin binding domain and after careful review are the only LP/P *APC* missense variants that we found in ClinVar in July 2018 that satisfy the ACMG/AMP guidelines.

Discussion {#sec013}
==========

*In silico* tools have been validated with accepted standards for relatively few genes, and the field would greatly benefit from refinement of standards for applying these tools. Factors that have been shown to be important for interpreting the output and reliability of computational algorithms include quality of PMSA (reviewed in \[[@pone.0233673.ref004]\]), and choice of variant data sets \[[@pone.0233673.ref032]\]. An important factor regarding data sets that has emerged recently is how predictors should not be evaluated on variants or proteins that were used to train their prediction models. This circularity could result in predictive values that are artificially inflated \[[@pone.0233673.ref032], [@pone.0233673.ref033]\], and could occur with either likely pathogenic or likely benign variants. We suggest that not enough attention has been assigned to an additional important factor, the likelihood that missense substitution is a major mechanism of pathogenicity for a gene.

Our analysis suggests possible revisions to the ACMG/AMP classification scheme for pathogenicity, which defines multiple criteria for evidence of benign or pathogenic effect, with strength ranging from "Supporting" to "Very Strong", and rules for combining different types of evidence \[[@pone.0233673.ref013]\]. For example, criterion BP1, "Missense variant in a gene for which primarily truncating variants are known to cause disease", is relevant to *APC*. By this criterion, any missense APC variant is given "Supporting" evidence, the lowest level, favoring benign classification of missense variants. Further study may help determine whether this criterion for benign classification should be upgraded from "Supporting" (for which estimated Odds of Pathogenicity is low \[[@pone.0233673.ref028]\], discussed below) to a higher level for these variants. The PP2 criterion for pathogenicity presupposes that missense is a common mechanism for mutation; future studies should assess whether it is being inappropriately used when missense is a rare or unknown mechanism for a given gene.

Our work confirms that PMSA construction remains a labor-intensive task \[[@pone.0233673.ref034]\]. Current automated tools do not align unstructured regions accurately, resulting in errors that require manual curation of protein and nucleotide sequences in order to optimally curate a full alignment. For many genes, accurate PMSA can prove important for *in silico* analysis of variant pathogenicity \[[@pone.0233673.ref004]\]. There is no consensus in the assessment of PMSA quality, although metrics have been proposed \[[@pone.0233673.ref035]\]. We and others have proposed that a PMSA should include enough sequences to contain three subs/site in order for predictions to be statistically robust \[[@pone.0233673.ref005], [@pone.0233673.ref006]\], and for APC we achieved this threshold with the addition of non-vertebrate sequences. We chose our sequences to be consistent with PMSAs of other cancer susceptibility genes for which *in silico* algorithms have proven to be valuable tools for variant classification. PMSAs for 15 such genes are posted on the Align-GVGD (<http://agvgd.hci.utah.edu/about.php>) web site. We hope to promote standardization of methods for the purposes of *in silico* analysis for variant classification. It remains to be determined whether a consistent set of sequences will be most appropriate for other gene sets. The creation and validation of our APC PMSA did identify interesting features of gene evolution and of genome annotation and analysis, and we anticipate that PMSAs across gene families are likely to elucidate specific structure-function relationships and molecular pathways of critical cellular functions. The full APC PMSA can be seen in [S1 Fig](#pone.0233673.s001){ref-type="supplementary-material"}, where it can be used for purposes that are beyond the scope of this paper.

One cannot assume that *in silico* tools that are valuable predictors for one gene will perform as well for other genes. The majority of *APC* missense variants in ClinVar are likely to be benign, given the paucity of missense pathogenic variants identified in over two decades of clinical *APC* testing. An example of a similar gene is *CDH1*, in which pathogenic missense variants also are rare. An expert panel studying the *CDH1* gene has recommended that computational methods not be used for missense *CDH1* variants \[[@pone.0233673.ref036]\]. Thus, tools that work well for genes that are commonly inactivated by missense changes \[[@pone.0233673.ref007], [@pone.0233673.ref011], [@pone.0233673.ref037], [@pone.0233673.ref038]\] can be misleading for genes that are rarely inactivated by missense. For such genes, traditional *in silico* tools will likely overestimate the probability of pathogenicity of any missense variant.

The ClinGen Sequence Variant Interpretation working group has estimated that the "Supporting" level of evidence confers approximately 2.08/1 odds in favor of pathogenicity \[[@pone.0233673.ref028]\], or a 67.5% probability of pathogenicity. Our current analyses of APC variants suggest that the likelihood that a missense APC variant is pathogenic is very low, perhaps lower than 1%. We base this conclusion on the observation that only 2 of 1924 missense variants in Clinvar (0.10%) are classified as pathogenic ([Table 3](#pone.0233673.t003){ref-type="table"}) after decades of analysis by testing labs and researchers. Despite this, our curated APC PMSA and several *in silico* prediction tools all predicted a significant fraction of missense variants to be pathogenic ([Table 4](#pone.0233673.t004){ref-type="table"}). The methods that we used varied widely in their predictions for APC VUS; predictions of Pathogenic or Likely Pathogenic ranged from 17.5% to 75%, all of which are higher than the likely figure by at least an order of magnitude. This provides mathematical support for not using *in silico* evidence in favor of pathogenicity (PP3 in the ACMG/AMP scheme \[[@pone.0233673.ref013]\]) for these genes. One approach might be to create a decision tree in which a gene must meet specific criteria before *in silico* evidence is applied. More work is needed in order to understand which genes require pre-curation to assess whether PMSA-based or other *in silico* methods are likely to be useful. A difference between functional or structural relevance to the protein and clinical relevance may occur if the assayed function is not crucial to the phenotype, or perhaps from domain redundancy or other protein structural features.

Another important factor regarding data sets is whether the subject was being tested because of clinical suspicion, or whether broad panel testing, whole exome or whole genome sequencing yielded a variant in the absence of any known clinical features. The degree of clinical suspicion is difficult to discern from the majority of ClinVar *APC* variants. The prior probability of pathogenicity \[[@pone.0233673.ref007]\] will be much lower for a variant discovered incidentally through whole exome sequencing compared with one identified through clinical testing because of a strong history of polyposis and/or colon cancer, with intermediate scenarios also possible.

Computational methods can be an excellent classifier for missense variants in hereditary cancer genes where missense is a common mechanism of pathogenicity \[[@pone.0233673.ref007]--[@pone.0233673.ref011]\]. However, known pathogenic APC missense germline variants are rare. It is possible that none exist outside of the first 15-amino acid repeat of the β-catenin binding domain, and it is unknown how many other pathogenic missense variants are located in this 15 amino acid repeat, complicating the use of computational tools. Further analysis of this region is necessary to understand the role of missense APC variants and the value of *in silico* algorithms. The β-catenin binding repeats may be the only specific region of 15 AA out of the 2843 AA of APC in which *in silico* methods may be predictive of clinical pathogenicity. A similar observation to the use of *in silico* analysis has been made regarding the BRCT domain of BRCA1 \[[@pone.0233673.ref004]\]. There may be characteristics of the APC gene and protein that confound the results of *in silico* algorithms. One plausible hypothesis for the failure of missense variants to abrogate APC function is the redundancy of APC important structural elements (armadillo repeats, β-catenin and axin binding sites) \[[@pone.0233673.ref029]\], so the inactivation of a single repeat might not eliminate binding to the target to a clinically relevant level.

Defining features that distinguish genes for which missense is a common (e.g., MMR genes \[[@pone.0233673.ref007]\]) versus uncommon (e.g., *CDH1* \[[@pone.0233673.ref036], [@pone.0233673.ref039]\], *RB1* \[[@pone.0233673.ref040]\]) pathogenic mechanism would significantly improve the application of *in silico* tools to variant classification. We propose that *in silico* methods to assess missense variants (PP3 and BP4 in the ACMG/AMP guidelines \[[@pone.0233673.ref013]\]) be used sparingly for any gene where strong evidence suggests that missense rarely causes pathogenicity. Future work might consider whether BP4 (concordance for "benign" classification among multiple methods) might be replaced by BP1 (truncation predominates, missense unlikely) in such cases. Our results suggest that a systematic study of variant pathogenicity and protein features such as domain structure is warranted to improve the use of predictive algorithms in hereditary cancer genes.

Supporting information {#sec014}
======================

###### Curated 10-species APC alignment.

PMSA was generated from the program Clustal Omega. Exon boundaries are labeled in red with a black background. The domains are highlighted throughout the alignment. Grey is oligomerization domain, red is Armadillo repeats, yellow is Beta Catenin Repeats, green is a sequence with homology to the herpes virus (PHA03307), turquoise is the Basic domain, and purple is the EB1 and HDLG binding site.

(PDF)

###### 

Click here for additional data file.

###### 38-species APC alignment.

PMSA was generated from the program Clustal Omega. No annotation is added.

(PDF)

###### 

Click here for additional data file.

###### Curated 9-species APC alignment.

PMSA was generated from the program Clustal Omega. Annotation as per [S1 Fig](#pone.0233673.s001){ref-type="supplementary-material"}.

(PDF)

###### 

Click here for additional data file.

###### Curated 8-species APC alignment.

PMSA was generated from the program Clustal Omega. Annotation as per [S1 Fig](#pone.0233673.s001){ref-type="supplementary-material"}.

(PDF)

###### 

Click here for additional data file.

We are grateful for ongoing illuminating discussions with our colleagues on the ClinGen Sequence Variant Interpretation Working group and the InSiGHT Variant Interpretation Committee.
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Dear Dr. Greenblatt,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Theauthors have showed that with PMSA they have reassigned 5/21 to be pathogenic, they should mention those 5 variants and discuss how this differs from the others and the location and consequences of the variants in addition to  addressing the points raised by reviewer 1.

We would appreciate receiving your revised manuscript by Apr 11 2020 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Obul Reddy Bandapalli, MSc, PhD

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements:

1\. Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at <http://www.plosone.org/attachments/PLOSOne_formatting_sample_main_body.pdf> and <http://www.plosone.org/attachments/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

2\. Thank you for stating the following in the Competing Interests section:

\"I have read the journal\'s policy and the authors of this manuscript have the following competing interests: MER and TP are employees of Ambry Genetics, Inc. No other authors have competing interests.\"

We note that one or more of the authors are employed by a commercial company: Ambry Genetics.

1.     Please provide an amended Funding Statement declaring this commercial affiliation, as well as a statement regarding the Role of Funders in your study. If the funding organization did not play a role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript and only provided financial support in the form of authors\' salaries and/or research materials, please review your statements relating to the author contributions, and ensure you have specifically and accurately indicated the role(s) that these authors had in your study. You can update author roles in the Author Contributions section of the online submission form.

Please also include the following statement within your amended Funding Statement.

"The funder provided support in the form of salaries for authors \[insert relevant initials\], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section."

If your commercial affiliation did play a role in your study, please state and explain this role within your updated Funding Statement.

2\. Please also provide an updated Competing Interests Statement declaring this commercial affiliation along with any other relevant declarations relating to employment, consultancy, patents, products in development, or marketed products, etc.  

Within your Competing Interests Statement, please confirm that this commercial affiliation does not alter your adherence to all PLOS ONE policies on sharing data and materials by including the following statement: \"This does not alter our adherence to  PLOS ONE policies on sharing data and materials." (as detailed online in our guide for authors <http://journals.plos.org/plosone/s/competing-interests>) . If this adherence statement is not accurate and  there are restrictions on sharing of data and/or materials, please state these. Please note that we cannot proceed with consideration of your article until this information has been declared.

Please include both an updated Funding Statement and Competing Interests Statement in your cover letter. We will change the online submission form on your behalf.

3\. We note that you have included the phrase "data not shown" in your manuscript. Unfortunately, this does not meet our data sharing requirements. PLOS does not permit references to inaccessible data. We require that authors provide all relevant data within the paper, Supporting Information files, or in an acceptable, public repository. Please add a citation to support this phrase or upload the data that corresponds with these findings to a stable repository (such as Figshare or Dryad) and provide and URLs, DOIs, or accession numbers that may be used to access these data. Or, if the data are not a core part of the research being presented in your study, we ask that you remove the phrase that refers to these data.

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: N/A

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: No

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: Prediction of pathogenicity of variants of unknown significance is a clinically important goal and in this study the authors have constructed a PMSA of APC to assist in variant prediction. Not all the steps in the description of how they made the PMSA are completely clear but overall it looks like the authors located as many complete APC protein sequences they could find, did a multiple sequence alignment and adjusted the MSA according to their best judgement as to how the sequence should align. Having constructed the PMSA 5 algorithms were applied that predict impact of AA substitutions to a PMSA they constructed for APC to see what they predicted at sites in APC listed as pathogenic or benign in ClinVar and scored how well each algorithm matched the ClinVar annotations.

As a non-bioinformatics specialist I found the paper very hard to follow and was not able to assess to my satisfaction the reliability of the variant prediction using the newly constructed PMSA. For example online 403 in the discussion the statement is made \"Our current analyses of APC variants suggest that the likelihood that a missense APC variant is pathogenic is far lower than 1%.\" However I could not find any reference to this in the results so have no idea how this figure was derived. While this conclusion may well be in the results somewhere, it is not obvious and I suspect many readers of PLOS One will have difficulty following the flow of the manuscript. I suggest the authors should revise the manuscript to more explicitly explain the various steps in the analyses and how they reach their conclusions.

Reviewer \#2: This is one of only two papers I have ever reviewed that I have recommended acceptance as is. It is excellent and a major advance in the field. The recommendation in the discussion that the ACMG/AMP criteria re APC variants needs amending is especially germane, and will be relevant to genes with similar modes of pathogenicity.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: Yes: Ian Frayling

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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We thank the reviewers and editor for their helpful comments. We are very happy that Reviewer 2 took such a positive view of the paper. Reviewer 1 and the editor each make one specific suggestion, which we have addressed as below. Also, we now provide the "data not shown".

1\. Reviewer 1 couldn't follow the conclusion that \"Our current analyses of APC variants suggest that the likelihood that a missense APC variant is pathogenic is far lower than 1%.\" We have modified this statement slightly, and provided the rationale, which is already in the manuscript on pages 11 and 12, and in Table 3. We think we have made this more clear:

\"Our current analyses of APC variants suggest that the likelihood that a missense APC variant is pathogenic is very low, perhaps lower than 1%. We base this conclusion on the observation that only 2 of 1924 missense variants in Clinvar (0.10%) are classified as pathogenic (Table 3) after decades of analysis by testing labs and researchers.\"

2\. The specific comment from the editor is slightly puzzling, but we think that we have found the source of the comment and edited the manuscript to clarify: "The authors have showed that with PMSA they have reassigned 5/21 to be pathogenic, they should mention those 5 variants and discuss how this differs from the others and the location and consequences of the variants in addition to addressing the points raised by reviewer 1."

We believe that the reviewer is referring to the sentence "When applied to 21 variants reported in ClinVar as Benign, the five methods ranged in accuracy from 76.2-100%" in the Abstract. We have clarified that we consider the variants to be securely classified as Benign. These variants are described in the manuscript on pages 12, 13, and 14, and in Tables 4, 5A, and 5B. We have edited sentences in the Abstract and in the text (p.13, line 292-294) to clarify that we consider these to be securely classified as Benign, and the discrepancy is due to the methods, not due to misclassification, as follows:

Abstract: "When applied to 21 missense variants reported in ClinVar and securely classified as Benign, the five methods ranged in accuracy from 76.2-100%."

Manuscript text: "For the n=21 variants securely classified in ClinVar as B/LB based on non-computational data, the prediction algorithms showed good concordance with each other and with the ClinVar classifications (Table 5A). "

3\. Data Not Shown

The "Data not shown" were the 8 sequence and 9 sequence alignments. These are now included as Supporting Figure 3 and 4.

4\. We have edited the Competing Interests section using the language provided in the Review.

###### 

Submitted filename: Response to Reviewers.pdf

###### 

Click here for additional data file.
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Dear Dr. Greenblatt,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication after internal evaluation of  the revised manuscript and found that the authors addressed the points raised by the reviewer/editor and found them to be satisfactory and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <https://www.editorialmanager.com/pone/>, click the \"Update My Information\" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

With kind regards,

Obul Reddy Bandapalli, MSc, PhD

Academic Editor

PLOS ONE
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Dear Dr. Greenblatt:

I\'m pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they\'ll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

If we can help with anything else, please email us at <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff
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Dr. Obul Reddy Bandapalli
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